scholarly journals New Heterometallic Compound as Luminescent Sensor for Detection of CS2 and Treatment Effect on Childhood Diabetes

2021 ◽  
Author(s):  
Wen-Hui Sun ◽  
Bing Ye
Keyword(s):  
Blood Glucose ◽  
High Selectivity ◽  
Hydrothermal Reaction ◽  
Childhood Diabetes ◽  
Rt Pcr ◽  
Luminescent Sensor ◽  
Intense Luminescence ◽  
Glucose Meter ◽  
Heterometallic Compound ◽  
Blood Glucose Meter

Abstract The hydrothermal reaction of Cd(NO3)2·4H2O, KNO3 with the dicarboxylate ligand of 2-aminoterephthalic acid (H2L) yields a new heterometallic coordination polymer with the formula of [CdK2(L)2(H2O)4]n (1). Compound 1 emits intense luminescence at ambient temperature and shows high selectivity and sensitivity for the detection of CS2. Serial biological experiments were conducted to evaluate the activity of the new compound on children diabetes. First of all, after the compound treatment, the blood glucose meter was used to measure the levels of body's blood sugar. In addition to this, the relative expression levels of the insulin receptor on the liver cells were determined with real time RT-PCR.

Blood glucose meter performance under hyperbaric oxygen conditions

2001 ◽  
Vol 305 (1-2) ◽  
pp. 81-87 ◽  
Author(s):  
David A Vote ◽  
Owen Doar ◽  
Richard E Moon ◽  
John G Toffaletti
Keyword(s):  
Blood Glucose ◽  
Hyperbaric Oxygen ◽  
Oxygen Conditions ◽  
Glucose Meter ◽  
Blood Glucose Meter

Comparison of the accuracy of measuring blood glucose in whole blood of arteriovenous mixed blood by two kinds of blood glucose meters

2021 ◽  
pp. 1-9
Author(s):  
Haifen Zhang ◽  
Shuhui Lailan ◽  
Shiyu Zhao ◽  
Qian Liu ◽  
Nina Fang ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Correlation Coefficient ◽  
Main Method ◽  
Maintenance Haemodialysis ◽  
Glucose Testing ◽  
Mixed Blood ◽  
Blood Glucose Testing ◽  
Glucose Meter ◽  
Arteries And Veins ◽  
Blood Glucose Meter

BACKGROUND: Portable blood glucose meters are the main method for detecting the blood glucose status of clinical patients. OBJECTIVE: To investigate the accuracy of detecting blood glucose in haemodialysis patients by sampling two blood glucose meters through the haemodialysis line. METHODS: Convenient sampling was used to select 80 patients with maintenance haemodialysis. The patients were sampled through the arterial end of the haemodialysis line within three minutes of being put on the machine. One specimen was tested by glycemeter1, which can identify the type of blood in the arteries and veins, and glycemeter2, which can only detect blood glucose in the capillaries for bedside blood glucose testing. The other specimen was sent to the laboratory biochemical analyser for blood glucose testing. RESULTS: When the blood glucose value of the first blood glucose meter (No. 1) was compared with the laboratory biochemical analyser, the correlation coefficient was r = 0.805 (p < 0.05), the out of value of the first blood glucose meter accounted for 4.4%, and the consistency reached 95% (p < 0.05). When the blood glucose value of the second blood glucose meter (No. 2) was compared with the laboratory biochemical analyser, the correlation coefficient was r = 0.800 (p < 0.05), the out of value of the second blood glucose meter accounted for 4.4%, and the consistency reached 95% (p < 0.05). CONCLUSIONS: For patients with maintenance haemodialysis, the blood glucose values detected by the two bedside blood glucose meters using arteriovenous mixed blood in the pipeline do not affect the accuracy and can respond more realistically.

The MAMICare Project

2018 ◽  
pp. 483-497
Author(s):  
Juan C. Lavariega ◽  
Gustavo A. Córdova ◽  
Lorena G. Gómez ◽  
Alfonso Avila
Keyword(s):  
Information Technology ◽  
Blood Glucose ◽  
Software Architecture ◽  
Rural Areas ◽  
Pulse Oximeter ◽  
Health Data ◽  
Glucose Meter ◽  
Blood Glucose Meter ◽  
Technology Solution ◽  
Health Sensors

This chapter is an updated version of a previous work about the authors' project on monitoring pregnancy progress in rural areas and/or areas with poor support of medical services. The project is based on an information technology solution based on mobile devices and health sensors such as electrocardiogram, stethoscope, pulse-oximeter, and blood-glucose meter to automatically collect relevant health data for monitoring pregnancy. In this chapter, the authors provide a detailed description of the software architecture of the system. They include a description of the test they have been performing and the difficulties they have faced for the complete implementation of their system.

scholarly journals Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)

2019 ◽  
Vol 13 (3) ◽  
pp. 498-506 ◽  
Author(s):  
Athena Philis-Tsimikas ◽  
Irene Stratton ◽  
Lone Nørgård Troelsen ◽  
Britta Anker Bak ◽  
Lawrence A. Leiter
Keyword(s):  
Patient Safety ◽  
Blood Glucose ◽  
Data Collection ◽  
Treatment Period ◽  
Collection System ◽  
Data Collection System ◽  
Protocol Amendment ◽  
Trial Conduct ◽  
Glucose Meter ◽  
Blood Glucose Meter

Background: A head-to-head trial (NCT03078478) between insulin degludec and insulin glargine U300 with the primary objective of comparing the risk of hypoglycemia is being conducted. During trial conduct, safety concerns related to the glycemic data collection system led to a postinitiation protocol amendment, described here. Methods: This randomized (1:1), open-label, treat-to-target, multinational trial was initiated in March 2017 with a planned treatment period of 52 weeks (16 weeks titration + 36 weeks maintenance). Overall, ~1600 insulin-experienced patients at risk of developing hypoglycemia based on predefined risk factors were included. The protocol amendment implemented in February 2018 resulted in assuring patient safety and an extension of the total treatment period up to 88 weeks (16 weeks titration + variable maintenance 1 + 36 weeks maintenance 2). The original glycemic data collection system (MyGlucoHealth blood glucose meter + electronic diary) was discontinued because of safety concerns and replaced with an Abbott blood glucose meter and paper diary to collect self-measured blood glucose and hypoglycemic episodes. The primary endpoint of number of severe or blood-glucose confirmed symptomatic hypoglycemic episodes will be evaluated with the same analysis duration and statistical methods as the original protocol. Only relevant changes were implemented to maintain patient safety while permitting evaluation of the scientific objectives of the trial. Conclusions: These observations highlight the importance of safety surveillance during trial conduct despite the use of currently marketed glucose monitoring devices. The prompt protocol amendment and ensuing actions ensured that the scientific integrity of the trial was not compromised.

314: ACCURACY OF OFF-LABEL USE OF BLOOD GLUCOSE METER IN THE CRITICAL CARE POPULATION

2020 ◽  
Vol 48 (1) ◽  
pp. 139-139
Author(s):  
Amy Stewart ◽  
Karen Seibert ◽  
Dana Villines ◽  
Joel Saeedi ◽  
Joumana Chaiban ◽  
...  
Keyword(s):  
Critical Care ◽  
Blood Glucose ◽  
Off Label Use ◽  
Off Label ◽  
Glucose Meter ◽  
Blood Glucose Meter ◽  
Label Use

System accuracy assessments with a blood glucose meter with combined glucose and ß-hydroxybutyrate measurement capabilities

2019 ◽  
Vol 19 (11) ◽  
pp. 1043-1048
Author(s):  
Sylvia Weissenbacher ◽  
Chen-Yu Yang ◽  
Tang-Chin Kuan ◽  
Filiz Demircik ◽  
Mina Hanna ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Meter ◽  
Accuracy Assessments ◽  
Blood Glucose Meter ◽  
Measurement Capabilities
Sign in / Sign up

Export Citation Format

Share Document